Citation Impact
Citing Papers
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
2009 Standout
DiarrheagenicEscherichia coli
1998 Standout
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
2007 Standout
Lipoprotein Lipase Links Dietary Fat to Solid Tumor Cell Proliferation
2011
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
The Antiinflammatory Effects of Aprotinin in Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass
1997
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells
2008
Triple negative breast cancer: unmet medical needs
2010
Pharmacologic Targeting of Hypoxia-Inducible Factors
2019 StandoutNobel
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
2007
Cancer–stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis
2012 StandoutNobel
Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes
2010
Hallmarks of Cancer: The Next Generation
2011 Standout
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy
2012
Is Expression or Activation of Src Kinase Associated with Cancer-Specific Survival in ER-, PR- and HER2-Negative Breast Cancer Patients?
2009
Neural regulation of hypoxia-inducible factors and redox state drives the pathogenesis of hypertension in a rodent model of sleep apnea
2015 StandoutNobel
Triple-Negative Breast Cancer
2010 Standout
Cancer statistics, 2024
2024 Standout
C1 inhibitor: molecular and clinical aspects
2005
Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor
2014 StandoutNobel
Reasons for breast cancer heterogeneity
2008
Operations on the thoracic aorta and hypothermic circulatory arrest: Is aprotinin safe?
1998
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Drugs to Minimize Perioperative Blood Loss in Cardiac Surgery
1997
Effects of aprotinin on blood loss, heparin monitoring tests, and heparin doses in patients undergoing coronary artery bypass surgery
1995
High-Dose ϵ-Aminocaproic Acid Versus Aprotinin: Antifibrinolytic Efficacy in First-Time Coronary Operations
1998
Regional Hemostatic Status and Blood Requirements After Total Knee Arthroplasty With and Without Tranexamic Acid or Aprotinin
2001
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
2013 Standout
Ruthenium Polypyridyl Complex Inhibits Growth and Metastasis of Breast Cancer Cells by Suppressing FAK signaling with Enhancement of TRAIL-induced Apoptosis
2015
Novel Treatment Approaches for Triple-Negative Breast Cancer
2010
Exercise Standards for Testing and Training
2013 Standout
Modulation of oxidative stress as an anticancer strategy
2013 Standout
Atherosclerosis: current pathogenesis and therapeutic options
2011 Standout
Triple negative breast cancer - prognostic factors and survival
2011
Ketamine: an update on the first twenty-five years of clinical experience
1989
Reduction in Costs, Blood Products, and Operating Time in Patients Undergoing Open Heart Surgery
1997
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
2003 Standout
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
2010 Standout
Tranexamic Acid and Aprotinin in Primary Cardiac Operations: An Analysis of 220 Cardiac Surgical Patients Treated with Tranexamic Acid or Aprotinin
2008
Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease∗∗∗∗A list of participating ESSENCE Study Group investigators may be found in N Engl J Med 1997;337:447–52.
2000
Hypoxia-inducible factor–dependent breast cancer–mesenchymal stem cell bidirectional signaling promotes metastasis
2012 StandoutNobel
How basal are triple‐negative breast cancers?
2008
Breast cancer genomes — form and function
2010
Role of Oxidative Modifications in Atherosclerosis
2004 Standout
The golden age: gold nanoparticles for biomedicine
2011 Standout
Aprotinin Reduces Cardiac Troponin I Release and Inhibits Apoptosis of Polymorphonuclear Cells During Off-Pump Coronary Artery Bypass Surgery
2007
Exercise training enhances endogenous fibrinolysis in peripheral arterial disease
2004
The contribution of thrombosis to the clinical expression of coronary atherosclerosis
1996
Half-dose aprotinin preserves hemostatic function in patients undergoing bypass operations
1995
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
2011 Standout
The effects of acute and chronic exercise on the vasculature
2010
Genomic Analysis of Reactive Astrogliosis
2012 Standout
Platelets in inflammation and atherogenesis
2005 Standout
CD26, let it cut or cut it down
1999
Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells
2006 StandoutNobel
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
The Emerging Hallmarks of Cancer Metabolism
2016 Standout
The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment
2010
Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer
2013 StandoutNobel
Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy
2002
Protein adsorption to oligo(ethylene glycol) self-assembled monolayers: Experiments with fibrinogen, heparinized plasma, and serum
2001
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012 Standout
Comparison of epsilon aminocaproic acid and low-dose aprotinin in cardiopulmonary bypass: efficiency, safety and cost
2001
A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease
1997 Standout
Aprotinin reduces blood loss in off-pump coronary artery bypass (OPCAB) surgery
2002
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
1999
Stabilisation of atherosclerotic plaques
2011
Gold nanoparticles in biomedical applications: recent advances and perspectives
2011 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Aprotinin Enhances the Endogenous Release of Interleukin-10 After Cardiac Operations
1998
Aprotinin in coronary operation with cardiopulmonary bypass: does “low-dose” aprotinin inhibit the inflammatory response?
2002
CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells
1998 StandoutNature
Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors
2015
Tamoxifen−Poly(ethylene glycol)−Thiol Gold Nanoparticle Conjugates: Enhanced Potency and Selective Delivery for Breast Cancer Treatment
2009
Regional Hemostatic Status and Blood Requirements After Total Knee Arthroplasty With and Without Tranexamic Acid or Aprotinin
2001
Platelet-Endothelial Cell Interactions During Ischemia/Reperfusion: The Role of P-Selectin
1998
Quantity and Quality of Exercise for Developing and Maintaining Cardiorespiratory, Musculoskeletal, and Neuromotor Fitness in Apparently Healthy Adults
2011 Standout
Semiconductor Quantum Dots for Bioimaging and Biodiagnostic Applications
2013
Comparison of Low-Molecular-Weight Heparin With Unfractionated Heparin Acutely and With Placebo for 6 Weeks in the Management of Unstable Coronary Artery Disease
1997
Anticoagulation Monitoring during Cardiac Surgery
1999
Drugs to Minimize Perioperative Blood Loss in Cardiac Surgery
1997
Aggregation-Induced Emission: Together We Shine, United We Soar!
2015 Standout
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial
2011 Standout
The development of anticancer ruthenium(ii ) complexes: from single molecule compounds to nanomaterials
2017 Standout
Is ε-Aminocaproic Acid as Effective as Aprotinin in Reducing Bleeding With Cardiac Surgery?
1999
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2006 Standout
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
2008
Tolerance of the hypertrophic heart to ischemia. Studies in compensated and failing dog hearts with pressure overload hypertrophy.
1990
Cancer statistics, 2016
2016 Standout
Blockade of NMDA Receptors and Apoptotic Neurodegeneration in the Developing Brain
1999 StandoutScience
Cancer in Adolescents and Young Adults
2016
Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
2012 StandoutNobel
A Multicenter, Double-Blind, Placebo-Controlled Trial of Aprotinin for Reducing Blood Loss and the Requirement for Donor-Blood Transfusion in Patients Undergoing Repeat Coronary Artery Bypass Grafting
1995
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding?
2005
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial
2010 Standout
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2008 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
The Association Between Idiopathic Hemolytic Uremic Syndrome and Infection by Verotoxin-Producing Escherichia coli
1985 Standout
Oxidized LDL and Malondialdehyde-Modified LDL in Patients With Acute Coronary Syndromes and Stable Coronary Artery Disease
1998
Platelet-Endothelial Cell Interactions During Ischemia/Reperfusion: The Role of P-Selectin
1998
Promoted Exchange Reaction between Alkanethiolate Self-Assembled Monolayers and an Azide-Bearing Substituent
2016 StandoutNobel
Works of W. Heller being referenced
Triple-negative breast cancer: therapeutic options
2007
Radiographic Contrast Media and the Coagulation and Complement Systems
1996
F XII
1990
Heparin-coated oxygenators significantly reduce contact system activation in an in vitro cardiopulmonary bypass model
1994
Aprotinin in cardiopulmonary bypass- effects on the Hageman factor (FXII)-Kallikrein system and blood loss
1992
Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage
1995
Changes in the Kallikrein-Kinin-System after Different Dose Regimen of Aprotinin during Cardiopulmonary Bypass Operation
1989
ASSOCIATION OF EXPOSED THOMSEN-FRIEDENREICH ANTIGEN (T ANTIGEN) AND ACUTE RENAL FAILURE IN SEPTIC PATIENTS
1984
The effects of aprotinin on chromogenic peptide substrate and other assays for components of the coagulation, fibrinolysis and plasma kallikrein systems
1994
103. Coagulation and fibrinolysis in patients with acute coronary syndromes in the follow up
1996
The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement
1993
Alterations of Coagulation and Fibrinolytic and Kallikrein-Kinin Systems in the Acute and Postacute Phases in Patients With Unstable Angina Pectoris
1995
[Hemostaseologic study in the use of midazolam-ketamine].
1986
The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement
1993
Function and energy-rich phosphate content of the hypertrophied ventricle after global ischemia and reperfusion
1986
Endothelial Tissue-Type Plasminogen Activator Release in Coronary Heart Disease
1998